Research and Markets: North American Markets for Facial Injectables from 2010 Through to 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/4b7e01/north_american_mar) has announced the addition of the "North American Markets for Facial Injectables 2010-2014" report to their offering.

The North American facial injectable market, comprising botulinum toxin (BTX), hyaluronic acid (HA) dermal filler, particle and polymer filler (PPF), and collagen filler product sales in Canada and the US, will undergo modest growth through 2014, fueled by high patient demand among American and Canadian consumers for procedures that help restore a more youthful appearance. The launch of new products, especially in the US market, will help promote market expansion as physicians gain access to new products that can enhance procedural outcomes and meet the needs of a variety of patients.

Greater competitive pressure throughout the forecast period will cause manufacturers to engage in marketing and promotional activity to differentiate their products from others, which will fuel greater awareness among both physicians and patients. The economic recession, however, had a particularly strong impact on the North American facial injectable market in the latter part of 2008 and, continuing through 2009, caused many patients to delay or forego facial injectable treatment, thus hindering procedural growth. Upon economic recovery, which Millennium Research Group assumes will begin in January 2010, the North American facial injectable market will resume positive growth as patients increasingly opt for facial injectable treatment to restore a youthful appearance.

Questions answered in this report:

  • In the US, two new products sanofi-aventis' Sculptra Aesthetic and Ipsen and Medicis Pharmaceuticals' Dysportwere launched in 2009 in the PPF and BTX markets, respectively. How did the launch of these two products affect market growth during the recession? How were sales of existing products in the BTX and PPF segments influenced by the launch? What do physicians think about using BOTOX Cosmetic versus Dysport, and how likely are they to adopt Dysport for use in their practices?
  • Injections into the glabellar complex and nasolabial fold were the most commonly performed facial injectable procedures in 2009 in North America. What types of facial injectable products were used in these facial indications? What other facial areas are popular for each of the different injectable products? Why are certain products used in particular areas of the face instead of competing products?
  • The North American collagen filler market will shrink drastically in 2011, following the withdrawal of both Allergan and ColBar LifeScience from the market in 2010. Which facial injectable market segments will benefit from the decline of the collagen filler market? Which competitors will remain in the collagen filler market? Will new collagen filler products be developed to fill the void left by Allergan and ColBar LifeScience?
  • Several new products are expected to gain approval in the US and Canadian facial injectable markets before 2014. What product segments will the new products enter? How will the launch of new products influence average selling prices (ASPs)? How will existing competitors react to increased market entry and heightened competitive pressure?

Scope:

Regions covered: US and Canada

Segmentation: Our analysis uses the following segmentation of the market:

Facial injectable procedures:

  • By product type
  • - BTX
  • - HA dermal fillers
  • - PPFs
  • - Collagen fillers

By facial area:

  • - Glabellar complex augmentation
  • - Nasolabial fold augmentation
  • - Forehead augmentation
  • - Periorbital area augmentation
  • - Lip augmentation
  • - Mouth area augmentation
  • - Cheek augmentation
  • - Other

Facial injectable products:

  • BTX
  • HA dermal fillers
  • PPFs
  • Collagen fillers

Market forecast features: Based on primary research with industry professionals and product end users, we use our proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, unit sales, ASPs, and market values over a 7-year period (20082014).

Competitive analysis: We provide a detailed analysis of the competitive landscape in the market, as well as market shares and qualitative discussions of the leading competitors in each market segment.

Companies Mentioned:

  • aap bio implants (Canderm Pharma)
  • Allergan
  • Anika Therapeutics (Coapt Systems)
  • Anteis
  • BioForm Medical
  • ColBar LifeScience
  • Fascia Biosystems
  • Ipsen (Medicis Pharmaceutical)
  • Laboratoires TEOXANE (Clarion Medical)
  • LifeCell
  • Mentor
  • Polymekon
  • Prollenium Medical Technologies
  • Q-Med (Medicis Pharmaceutical)
  • sanofi-aventis (Dermik Laboratories)
  • Suneva Medical

Note: Distributors are indicated in parentheses after manufacturers

For more information visit http://www.researchandmarkets.com/research/4b7e01/north_american_mar

Source: Millennium Research Group

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716